Prestige Consumer Healthcare Inc. (NYSE:PBH) Receives $93.33 Consensus PT from Analysts

Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Get Free Report) have received an average rating of "Moderate Buy" from the six brokerages that are presently covering the firm, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $93.33.

PBH has been the subject of several analyst reports. Oppenheimer raised their price target on shares of Prestige Consumer Healthcare from $87.00 to $93.00 and gave the company an "outperform" rating in a research report on Thursday, February 13th. Canaccord Genuity Group boosted their price objective on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a "buy" rating in a research note on Friday, February 7th. Wall Street Zen upgraded Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research note on Saturday, May 17th. DA Davidson boosted their price target on shares of Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a "buy" rating in a research report on Friday, February 7th. Finally, Royal Bank of Canada raised shares of Prestige Consumer Healthcare to a "hold" rating in a research note on Thursday, May 8th.

Insider Buying and Selling at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, SVP Mary Beth Fritz sold 1,678 shares of the company's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $90.00, for a total value of $151,020.00. Following the sale, the senior vice president now directly owns 17,157 shares of the company's stock, valued at approximately $1,544,130. This represents a 8.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.60% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Prestige Consumer Healthcare

A number of large investors have recently bought and sold shares of the business. Kestra Investment Management LLC purchased a new stake in shares of Prestige Consumer Healthcare during the fourth quarter worth about $27,000. CIBC Private Wealth Group LLC boosted its holdings in Prestige Consumer Healthcare by 48.9% in the 4th quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company's stock worth $34,000 after buying an additional 152 shares during the last quarter. Opal Wealth Advisors LLC purchased a new stake in Prestige Consumer Healthcare during the 1st quarter worth approximately $38,000. Headlands Technologies LLC acquired a new position in shares of Prestige Consumer Healthcare during the fourth quarter valued at approximately $40,000. Finally, Geneos Wealth Management Inc. boosted its stake in shares of Prestige Consumer Healthcare by 92.8% in the first quarter. Geneos Wealth Management Inc. now owns 559 shares of the company's stock worth $48,000 after acquiring an additional 269 shares during the last quarter. Institutional investors and hedge funds own 99.95% of the company's stock.

Prestige Consumer Healthcare Trading Down 0.3%

NYSE:PBH traded down $0.25 during midday trading on Monday, reaching $84.55. 28,764 shares of the stock traded hands, compared to its average volume of 298,226. The stock has a market capitalization of $4.18 billion, a P/E ratio of 19.79, a PEG ratio of 2.69 and a beta of 0.44. The company has a fifty day moving average of $83.58 and a 200 day moving average of $82.48. The company has a debt-to-equity ratio of 0.56, a quick ratio of 2.20 and a current ratio of 3.68. Prestige Consumer Healthcare has a 12 month low of $63.79 and a 12 month high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported $1.32 earnings per share for the quarter, beating the consensus estimate of $1.30 by $0.02. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. The business had revenue of $296.52 million for the quarter, compared to analysts' expectations of $289.36 million. During the same quarter in the previous year, the business posted $1.02 earnings per share. The firm's revenue for the quarter was up 7.0% compared to the same quarter last year. On average, research analysts predict that Prestige Consumer Healthcare will post 4.5 EPS for the current year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.